Actelion shareholders approve J&J takeover and Idorsia spin-off
The shareholders of the Swiss biotech company Actelion approved the acquisition by Johnson & Johnson (JNJ). As a reminder, J&J offered to buy Actelion for $30 billion, and now the acquisition could be completed by…
Read More